Journal of Affective Disorders
January 21, 2026
Jan Sarlon, Deanne Thomi, Annette B Brühl et al.
1 citation
Treatment-resistant depression (TRD) imposes major individual and societal burden, with few therapeutic options. Intranasal esketamine is approved but limited by cost and accessibility, prompting interest in alternatives. To assess non-inferiority of racemic ketamine versus esketamine in a real-world setting. We performed a single-centre, retrospective observational study emulating a randomized...
Psychiatry research. Neuroimaging
July 1, 2025
Anna Monn, Corinne Eicher, Annia Rüesch et al.
2 citations
Treatment-resistant depression (TRD) is associated with reduced quality of life and elevated mortality, posing a major challenge to psychiatric care. After non-response to conventional treatments, next-level interventions such as (es)ketamine are recommended, though remission rates remain variable. Identifying reliable markers of treatment response is therefore critical. Recent evidence...
European Archives of Psychiatry and Clinical Neuroscience
June 1, 2025
Jan Sarlon, Else Schneider, Annette B Brühl et al.
2 citations
Mindfulness-based interventions (MBI) are effective in relapse prevention in Major Depressive Disorder (MDD). Internet-based interventions have been demonstrated to be effective in the treatment of MDD. Consequently, the integration of MBI through mobile applications emerges as a promising supplementary intervention for MDD, contributing to the augmentation of mental health services,...
Therapeutische Umschau. Revue therapeutique
April 1, 2025
Tobias Bracht, Daniela Hubl, Kristina Adorjan et al.
1 citation
Depression is one of the most common mental disorders. The effectiveness of pharmacological and psychotherapeutic treatments is well documented. Remission rates are around 67 % for pharmacological antidepressant initial and secondary treatment of a depressive episode in unipolar disorders. However, patients with a depressive episode who do not respond to at least two successive attempts at...
Journal of Psychiatric Research
May 1, 2024
Michael Colla, Benjamin Offenhammer, Hanne Scheerer et al.
23 citations
We investigated the antidepressant effects of a novel oral prolonged-release formulation of racemic ketamine (KET01) in patients suffering from treatment-resistant depression (TRD) as add-on therapy. Patients were randomized to an additional 160 mg/day or 240 mg/day KET01 or placebo for 14 days. The primary endpoint was change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores from...
Frontiers in Psychiatry
January 23, 2024
Johannes Hauser, Jan Sarlon, Timur Liwinski et al.
10 citations
BackgroundAlthough the effectiveness of (es)ketamine for therapy-resistant depression (TRD) has been established, potential treatment-limiting factors include side effects like dissociation, anxiety, or elevated blood pressure. Music can reduce stress and negative emotions as anxiety. This study aimed to investigate the impact of listening to music during intranasal (es)ketamine administration...
Biological Psychology
September 1, 2016
J Lutz, Annette B Brühl, Hanne Scheerer et al.
Mindful self-awareness is central to mindfulness meditation and plays a key role in its salutary effects. It has been related to decreased activation in cortical midline structures (CMS) and amygdala, and increased activation in somatosensory regions. However, findings in untrained individuals are contradictory, and scarce in experienced meditators. Using fMRI, we investigated experienced...
Neuroimage
2016
J Lutz, Annette B Brühl, N Doerig et al.
Mental health benefits of mindfulness techniques are thought to involve changes in self-processing, such as decreased attachment to the self, higher self-compassion and lower emotional reactivity to inner experience. However, self-related emotion processing in regular mindfulness practitioners is not extensively studied. In the current work we investigate differential neural and behavioral...